The newest developments in anti-HIV-1 drugs

Yaoxue Xuebao

Volumn 45, Issue 2, 2010, Pages 194-204

  Zhang, Xing Quan ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Drug resistance strain; Drug drug interaction; Entry inhibitor; Highly active antiretroviral therapy; Integrase inhibitor; Metabolic complication; Protease inhibitor; Reverse transcriptase inhibitor

Indexed keywords

2',3' DIDEOXY 3' FLUOROGUANOSINE; 5 [3,5 DIETHYL 1 (2 HYDROXYETHYL) 4 PYRAZOLYLOXY] 1,3 BENZENEDINITRILE; 8 [4 (2 BUTOXYETHOXY)PHENYL] 1,2,3,4 TETRAHYDRO 1 ISOBUTYL N [4 (1 PROPYL 1H IMIDAZOL 5 YLMETHYLSULFINYL)PHENYL] 1 BENZAZOCINE 5 CARBOXAMIDE; ABACAVIR; AMPRENAVIR; ANTI HUMAN IMMUNODEFICIENCY VIRUS AGENT; APRICITABINE; ATAZANAVIR; BEVIRIMAT; BILR 355 BS; DARUNAVIR; DELAVIRDINE; DIDANOSINE; EFAVIRENZ; ELVITEGRAVIR; ELVUCITABINE; EMTRICITABINE; ENFUVIRTIDE; ETRAVIRINE; FOSAMPRENAVIR; GRZ 105655; GSK 364735; HGS 004; IDX 12899; IDX 12989; INDINAVIR; INTEGRASE INHIBITOR; LAMIVUDINE; LOPINAVIR; MARAVIROC; NELFINAVIR; NEVIRAPINE; NUCLEOSIDE ANALOG; PPL 100; PROTEINASE INHIBITOR; RALTEGRAVIR; RITONAVIR; RNA DIRECTED DNA POLYMERASE INHIBITOR; RO 140; SAQUINAVIR; STAVUDINE; TENOFOVIR; TIPRANAVIR; TNS 355; UNCLASSIFIED DRUG; UNINDEXED DRUG; ZALCITABINE; ZIDOVUDINE;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; ANTIVIRAL ACTIVITY; ARTICLE; CD4 LYMPHOCYTE COUNT; DRUG STRUCTURE; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; VIRUS REPLICATION;

ANTI-HIV AGENTS; ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; CYCLOHEXANES; DRUG RESISTANCE, VIRAL; HIV ENVELOPE PROTEIN GP41; HIV FUSION INHIBITORS; HIV INFECTIONS; HIV INTEGRASE INHIBITORS; HIV PROTEASE INHIBITORS; HIV REVERSE TRANSCRIPTASE; HIV-1; HUMANS; MOLECULAR STRUCTURE; PEPTIDE FRAGMENTS; PYRROLIDINONES; SAQUINAVIR; TRIAZOLES; VIRUS REPLICATION; ZIDOVUDINE;

EID: 77950920637     PISSN: 05134870     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (20)

1. Sobieszczyk ME, Taylor BS, Hammer SM. Antiretroviral agents [M]//Richman DD, Whiteley RJ, Hayden FG. Clinical Virology. 3rd ed. Washington DC: ASM Press, 2009: 167-216.
2. Guatelli JC, Siliciano RE, Daniel R, et al. Human immunodeficiency virus [M]// Richman DD, Whiteley RJ, Hayden FG. Clinical Virology. 3rd ed. Washington DC: ASM Press, 2009: 737-783.
3. Zhang XQ. AIDS and anti-HIV-1 drugs [M]//Chen HS, Zhang XQ. Antivirus Drugs: Methods and Applications Beijing: Chemical Industry Press, 2006: 353-384.
4. Chen HS, Zhang XQ. Anti-viral drugs [M]//Li JT. Clinical Pharmacology. Beijing: People's Medical Publishing House, 2007: 1163-1219.
5. Pommier Y, Johnson AA, Marchand C. Integrase inhibitors to treat HIV/AIDS [J]. Nat Rev Drug Discov, 2005, 4: 236-248.
6. Wilkin TJ, Taylor B, Olender S, et al. Advances in antiretroviral therapy [J]. Top HIV Med, 2009, 17: 68-88.
7. Wang L, Zhang XQ, Chen HS, et al. Improved synthesis and pharmacological evaluation of racemic 11-demethylcalanolide A [J]. Acta Pharm Sin 2008, 43: 707-718.
8. Chen HS. Antiviral Chinese medicinal herbs and their active components [M]//Chen HS, Zhang XQ. Antivirus Drugs: Methods and Applications. Beijing: Chemical industry Press, 2006: 269-286.
9. Kuritzkes DR. HIV resistance: frequency, testing, mechanisms [J]. Top HIV Med, 2007, 15: 150-154.
10. Zhang XQ. Viral gene mutation and drug resistance testing [M]//Chen HS, Zhang XQ. Antivirus Drugs: Methods and Applications. Beijing: Chemical Industry Press, 2006: 113-122.
11. Johnson VA, Brun-Vezinet F, Clotet F, et al. Update of the drug resistance mutations in HIV-1: Spring 2008 [J]. Top HIV Med, 2008, 16: 62-68.
12. Wohl DA, McComsey G, Tebas P, et al. Current concepts in the diagnosis and management of metabolic complications of HIV infections and its therapy [J]. CID, 2006, 434: 645-653. (Pubitemid 44267129)
13. Schambelan M, Benson CA, Carr A, et al. Management of metabolic complications association with antiretroviral therapy for HIV-1 infection: recommendations of an international AIDS society-USA panel [J]. J Acquir Immune Defic Syndr, 2002, 31: 257-275. (Pubitemid 35278626)
14. Currier JS, Havlir DV. Complications of HIV disease and therapy [J]. Top HIV Med, 2007, 15:40-47.
15. Grinspoon S, Carr A. Cardiovascular risk and body-fat abnormalities [J]. N Engl J Med, 2005, 1: 48-62.
16. Currier JS. Update on cardiovascular complications in HIV infection [J]. Top HIV Med, 2009, 17: 98-103.
17. Adeyemi O. Cardiovascular risk and management in HIV-infected patients [J]. Top HIV Med, 2007, 15: 159-162.
18. Murdoch DM, Venter WDF, Annelies VR, et al. Immune reconstitution inflammatory syndrome (IRIS): review of common infectious manifestations and treatment options [J]. AIDS Res Ther, 2007, 4: 9.
19. Aberg JA. Drug-drug interactions with newer antiretroviral agents [J]. Top HIV Med, 2008, 16: 146-150.
20. Back DJ. Drug-drug interactions that matter [J]. Top HIV Med, 2006, 14: 88-92.